| Nome |
# |
|
Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis, file 726b0d4f-665e-4b42-ad03-d2355fc59360
|
39
|
|
Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation, file e4233f17-ddc0-2860-e053-6605fe0a460a
|
34
|
|
Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies, file e4233f17-a8a0-2860-e053-6605fe0a460a
|
23
|
|
The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy, file e4233f17-76f6-2860-e053-6605fe0a460a
|
21
|
|
Ambulatory blood pressure and risk of new-onset atrial fibrillation in treated hypertensive patients, file e4233f18-5acb-2860-e053-6605fe0a460a
|
19
|
|
Clustering of blood cell count abnormalities and future risk of death, file e4233f18-8ca9-2860-e053-6605fe0a460a
|
17
|
|
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs, file e4233f17-e195-2860-e053-6605fe0a460a
|
15
|
|
Prognostic Significance of Chest Imaging by LUS and CT in COVID-19 Inpatients: The ECOVID Multicenter Study, file e4233f18-b687-2860-e053-6605fe0a460a
|
15
|
|
Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis, file e4233f18-6b54-2860-e053-6605fe0a460a
|
14
|
|
Predictive Value of Left Atrial and Ventricular Strain for the Detection of Atrial Fibrillation in Patients With Cryptogenic Stroke, file 55e453f9-b432-4060-b1a1-0d06870743a7
|
13
|
|
Effects of endurance, resistance and neuro-muscular electrical stimulation trainings to the anthropometric and functional mobility domains in elderly, file e4233f17-8fdc-2860-e053-6605fe0a460a
|
13
|
|
The Impact of Physical Activity and Inactivity on Cardiovascular Risk across Women’s Lifespan: An Updated Review, file 35bc40bc-509c-4c38-a5a5-2ca418512848
|
12
|
|
Prediction of Masked Uncontrolled Hypertension Detected by Ambulatory Blood Pressure Monitoring, file d6083d94-222b-4f68-9e4e-8bd8ec81a9f9
|
12
|
|
Echocardiographic screening for the anomalous aortic origin of coronary arteries, file e4233f18-32f1-2860-e053-6605fe0a460a
|
10
|
|
Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation, file e4233f18-3cbf-2860-e053-6605fe0a460a
|
10
|
|
Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome, file e4233f19-117c-2860-e053-6605fe0a460a
|
9
|
|
Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance, file e4233f15-c328-2860-e053-6605fe0a460a
|
8
|
|
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance", file e4233f15-bc43-2860-e053-6605fe0a460a
|
7
|
|
Increased left atrial size in obese children and its association with insulin resistance: a pilot study, file e4233f15-bf32-2860-e053-6605fe0a460a
|
7
|
|
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19, file e4233f18-e492-2860-e053-6605fe0a460a
|
7
|
|
Sex Differences in Heart Failure: What Do We Know?, file 760d95d7-80fe-4700-8d68-a222d7852fb9
|
6
|
|
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation, file 15402aae-fa58-4576-b438-c6bbafc36685
|
5
|
|
Case Report: Mitral Valve Involvement and First-Degree Atrial-Ventricular Block in Two Patients With Multisystem Inflammatory Syndrome in Children, file e4233f18-e00f-2860-e053-6605fe0a460a
|
5
|
|
Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19, file 76a0516d-d512-4706-b5da-3cfb5244473f
|
4
|
|
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease, file e4233f14-f17c-2860-e053-6605fe0a460a
|
3
|
|
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin – a persisting dilemma, file e4233f14-ff20-2860-e053-6605fe0a460a
|
3
|
|
The left atrial appendage: from embryology to prevention of thromboembolism, file e4233f15-9587-2860-e053-6605fe0a460a
|
3
|
|
Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects, file e4233f15-c32d-2860-e053-6605fe0a460a
|
3
|
|
Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension, file e4233f15-c52e-2860-e053-6605fe0a460a
|
3
|
|
AF: current and forthcoming antithrombotic therapies, file e4233f15-cc29-2860-e053-6605fe0a460a
|
3
|
|
Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation ∗, file e4233f17-719c-2860-e053-6605fe0a460a
|
3
|
|
Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin, file e4233f17-e456-2860-e053-6605fe0a460a
|
3
|
|
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors, file e4233f14-f8cf-2860-e053-6605fe0a460a
|
2
|
|
Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban, file e4233f15-042e-2860-e053-6605fe0a460a
|
2
|
|
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper, file e4233f15-a88d-2860-e053-6605fe0a460a
|
2
|
|
Non-vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation - An Updated Meta-analysis, file e4233f15-adbf-2860-e053-6605fe0a460a
|
2
|
|
Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination, file e4233f15-bb6e-2860-e053-6605fe0a460a
|
2
|
|
Dabigatran as an alternative to warfarin for the prevention of thromboembolism in atrial fibrillation, file e4233f15-bfa4-2860-e053-6605fe0a460a
|
2
|
|
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials, file e4233f15-c1c1-2860-e053-6605fe0a460a
|
2
|
|
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects, file e4233f15-c315-2860-e053-6605fe0a460a
|
2
|
|
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W, file e4233f15-c32a-2860-e053-6605fe0a460a
|
2
|
|
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease, file e4233f15-c373-2860-e053-6605fe0a460a
|
2
|
|
Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions, file e4233f15-c37e-2860-e053-6605fe0a460a
|
2
|
|
Facilitated PCI: Rationale, current evidence, open questions and future directions, file e4233f15-c385-2860-e053-6605fe0a460a
|
2
|
|
The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?, file e4233f15-c443-2860-e053-6605fe0a460a
|
2
|
|
Genetic determinants of blood pressure responses to caffeine drinking, file e4233f15-c450-2860-e053-6605fe0a460a
|
2
|
|
Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents, file e4233f15-c4c4-2860-e053-6605fe0a460a
|
2
|
|
Measurements of thromboxane production and their clinical significance in coronary heart disease, file e4233f15-c532-2860-e053-6605fe0a460a
|
2
|
|
New anticoagulants for atrial fibrillation, file e4233f15-c631-2860-e053-6605fe0a460a
|
2
|
|
Impact of antiplatelet therapy in heart disease, file e4233f15-c7cf-2860-e053-6605fe0a460a
|
2
|
|
Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial, file e4233f15-cbba-2860-e053-6605fe0a460a
|
2
|
|
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy, file e4233f17-7b1c-2860-e053-6605fe0a460a
|
2
|
|
The legacy of ISCHEMIA, file e4233f17-d249-2860-e053-6605fe0a460a
|
2
|
|
La gestione del rischio tromboembolico nei pazienti con fibrillazione atriale in Italia: Dati al follow-up del Registro Europeo PREFER in AF, file e4233f17-e132-2860-e053-6605fe0a460a
|
2
|
|
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries, file e4233f17-e198-2860-e053-6605fe0a460a
|
2
|
|
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions, file e4233f18-d0b7-2860-e053-6605fe0a460a
|
2
|
|
Predictors of Mortality and Cardiovascular Outcome at 6 Months after Hospitalization for COVID-19, file e4233f18-eef3-2860-e053-6605fe0a460a
|
2
|
|
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects, file e4233f14-febc-2860-e053-6605fe0a460a
|
1
|
|
Aspirina ed ACE-inibitori. Una partita ancora aperta?, file e4233f14-ff1d-2860-e053-6605fe0a460a
|
1
|
|
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe., file e4233f15-bd64-2860-e053-6605fe0a460a
|
1
|
|
Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry, file e4233f15-bf2a-2860-e053-6605fe0a460a
|
1
|
|
Coffee and Hypertension: A Focus on Contrasting Acute and Chronic Effects and Nutrigenetics, file e4233f15-c334-2860-e053-6605fe0a460a
|
1
|
|
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial, file e4233f15-c43d-2860-e053-6605fe0a460a
|
1
|
|
Increased short-term blood pressure variability is associated with early left ventricular systolic dysfunction in newly diagnosed untreated hypertensive patients., file e4233f15-c4b6-2860-e053-6605fe0a460a
|
1
|
|
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences, file e4233f15-c4b8-2860-e053-6605fe0a460a
|
1
|
|
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery, file e4233f15-c5e8-2860-e053-6605fe0a460a
|
1
|
|
Antithrombotic therapy in atrial fibrillation: state of the art and perspectives., file e4233f15-c68c-2860-e053-6605fe0a460a
|
1
|
|
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial, file e4233f17-e12e-2860-e053-6605fe0a460a
|
1
|
|
Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies, file e4233f17-e130-2860-e053-6605fe0a460a
|
1
|
|
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease, file e4233f17-e1d1-2860-e053-6605fe0a460a
|
1
|
|
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence, file e4233f17-e214-2860-e053-6605fe0a460a
|
1
|
|
Mortality benefit with different antithrombotic therapies in patients with stable vascular disease: from pathophysiology to the clinical impact in the real world. The COMPASS study, file e4233f17-e216-2860-e053-6605fe0a460a
|
1
|
|
Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type, file e4233f17-e218-2860-e053-6605fe0a460a
|
1
|
|
Edoxaban for the Prevention of Thromboembolism in Patients with Atrial Fibrillation and Bioprosthetic Valves, file e4233f17-e453-2860-e053-6605fe0a460a
|
1
|
|
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF, file e4233f17-e458-2860-e053-6605fe0a460a
|
1
|
|
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry, file e4233f17-e464-2860-e053-6605fe0a460a
|
1
|
| Totale |
418 |